Clinical Trial

A Phase Ⅲ Clinical Trial of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell) in Booster Vaccination

Unknown Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated July 25, 2024 (before its estimated June 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
A Phase Ⅲ Clinical Trial of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell) in Booster Vaccination to Evaluate Efficacy, Safety and Immunogenicity
Protocol Amendment History 1 change
critical Trial status changed: Not Yet Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT05911061
Lead Sponsor WestVac Biopharma Co., Ltd.
Conditions COVID-19
Enrollment 4,950 participants
Start Date 2024-12-30
Primary Completion 2025-06-30 (estimated)
Study Completion 2025-12-30 (estimated)
Updated on ClinicalTrials.gov 2024-07-25